Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Cardiovascular complications account for the highest mortality in type 2 diabetic patients,
mainly due to coronary artery disease (CAD). Most of the attention in treating CAD in type 2
diabetes is understandably directed toward treating coronary artery conditions. However there
are other treatable culprits in these patients.
Left ventricular hypertrophy (LVH) is widespread in type 2 diabetic patients with CAD, even
in the absence of hypertension. It is a strong predictor of cardiovascular events and
all-cause mortality. Regression of LVH has been associated with an improved prognosis,
independent of change in blood pressure (BP). Therefore, cardiovascular events and mortality
in type 2 diabetes with CAD might will be reduced if the investigators can find novel
therapies to regress LVH.
Alpha-lipoic acid reduces oxidative stress which then regresses LVH. Alpha-lipoic acid can
improve endothelial function in diabetic conditions. Hence, the main aim of this study was to
assess whether alpha-lipoic acid could regress LVM in type 2 diabetic patients with CAD.
Phase:
Phase 4
Details
Lead Sponsor:
Wuhan General Hospital of Guangzhou Military Command